Nuwellis, Inc. (NUWE) AI Stock Summary

Snapshot

Nuwellis is a tiny medical device manufacturer facing severe financial distress. The company received a going-concern warning from auditors and has a negative cash runway, meaning it has already burned through its cash cushion at current spending rates. With just $1.1M in cash and annual free cash flow burn of $10.9M, the business cannot fund itself. While preliminary Q2 2026 data shows 14% revenue growth, the company loses significantly more money than it makes in sales. A massive 1-for-35 reverse split was executed in June 2026 solely to prevent delisting from the Nasdaq.

What's Happening Right Now

• Mon 27th Jul '26 · Earnings: Preliminary Q2 2026 revenue showed 14% year-over-year growth, with 20% growth for the first half of the year driven by the Aquadex Ultrafiltration platform.
• Wed 24th Jun '26 · Corporate Action: The Board approved a 1-for-35 reverse stock split to regain compliance with Nasdaq minimum bid price requirements.
• Thu 18th Jun '26 · Management: Nuwellis appointed Michael McCormick as Chief Executive Officer, replacing John Erb who transitioned to Executive Chairman.
• Mon 8th Jun '26 · Financing: The company closed a $6.0 million registered public offering, selling shares and pre-funded warrants to fund operations.

Ownership

Institutions hold 9.0%, insiders hold 0.0%.

Bottom Line

Nuwellis is a distressed company fighting for survival rather than a stable operating business. The combination of a going-concern warning, exhausted cash runway, and a reverse split signals extreme risk regardless of recent revenue growth. The stock has already collapsed 99.5% from its 52-week high. A reader needs to view this as a high-risk turnaround situation dependent on constant capital raises.